top
Gilgamesh Pharmaceuticals Completes Phase 1 SAD Clinical Trial of GM-2505
NRx Pharmaceuticals Founder Jonathan Javitt Discusses Company’s Mission, Pipeline in Nasdaq Interview
Compass Launches Phase 3 Psilocybin Study in UK
NRx Pharmaceuticals Plans to Spin Off Ketamine-Focused Company
Canadian Senate Urges Immediate Action for Veterans’ Access to Psychedelic Therapies
1 2